March 24, 2014Journal of the American Heart Association265 citationsOpen Access
View Full PaperCancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies
Structured PICO
P
Population
63-year-old man with well-controlled hypertension and diffuse large B-cell lymphoma
I
Intervention
Doxorubicin-containing chemotherapy regimen
The text presents a clinical vignette of a 63-year-old man who developed heart failure symptoms and reduced LVEF 3 months after starting doxorubicin-containing chemotherapy, introducing a review on cancer therapy-induced cardiotoxicity.
Abstract
T he patient is a 63-year-old man with a history of well- controlled hypertension who is diagnosed with diffuse large B-cell lymphoma and treated with a doxorubicincontaining chemotherapy regimen. During therapy, he is continued on hydrochlorothiazide for his hypertension. Three months later, he complains of dyspnea on exertion and mild lower extremity edema. A transthoracic echocardiogram reveals a moderately reduced left ventricular ejection fraction (LVEF), which is new compared with a study performed before he underwent chemotherapy.